Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Share-based Compensation (2016 - 2025)

CorMedix's Share-based Compensation history spans 13 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 200.71% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $13.8 million, up 110.74%, while the annual FY2025 figure was $13.8 million, 125.68% up from the prior year.
  • Share-based Compensation for Q4 2025 was $3.6 million at CorMedix, down from $4.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.1 million in Q3 2025 and bottomed at -$1.1 million in Q2 2022.
  • The 5-year median for Share-based Compensation is $1.5 million (2024), against an average of $1.8 million.
  • The largest annual shift saw Share-based Compensation plummeted 207.75% in 2022 before it soared 1758.6% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2021, then plummeted by 30.26% to $874051.0 in 2022, then plummeted by 92.22% to $68000.0 in 2023, then soared by 1655.15% to $1.2 million in 2024, then soared by 200.71% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Share-based Compensation are $3.6 million (Q4 2025), $4.1 million (Q3 2025), and $2.7 million (Q2 2025).